No Cover Image

Journal article 571 views 80 downloads

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently

Marc Evans, Angharad R. Morgan, Steve Bain Orcid Logo, Sarah Davies, Umesh Dashora, Smeeta Sinha, Samuel Seidu, Dipesh C. Patel, Hannah Beba, W. David Strain

Diabetes Therapy, Volume: 13, Issue: 5, Pages: 889 - 911

Swansea University Author: Steve Bain Orcid Logo

  • 59763.pdf

    PDF | Version of Record

    Copyright: The Author(s) 2022. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

    Download (654.49KB)

Check full text

DOI (Published version): 10.1007/s13300-022-01242-y

Abstract

Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the cardiovascular, renal and metabolic systems, through a continuous chain of events refe...

Full description

Published in: Diabetes Therapy
ISSN: 1869-6953 1869-6961
Published: Springer Science and Business Media LLC 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa59763
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-04-04T15:08:11Z
last_indexed 2023-01-11T14:41:15Z
id cronfa59763
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-08-05T12:24:45.4909389</datestamp><bib-version>v2</bib-version><id>59763</id><entry>2022-04-04</entry><title>Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-04-04</date><deptcode>BMS</deptcode><abstract>Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the cardiovascular, renal and metabolic systems, through a continuous chain of events referred to as &#x2018;the cardiorenal metabolic continuum&#x2019;. Increasing evidence suggests that sodium&#x2013;glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes. Despite this robust evidence base, the complexity of label indications and misconceptions concerning potential side effects have resulted in a lack of clear understanding in primary care regarding the implementation of SGLT2is in clinical practice. With this in mind, we provide an overview of the clinical and economic benefits of SGLT2is across the cardiorenal metabolic continuum together with practical considerations in order to help address some of these concerns and clearly define the role of SGLT2is in primary care as a holistic outcomes-driven treatment with the potential to reduce disease burden across the cardiorenal metabolic spectrum.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>13</volume><journalNumber>5</journalNumber><paginationStart>889</paginationStart><paginationEnd>911</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>Cardiorenal metabolic continuum; Chronic kidney disease; Diabetes; Heart failure; SGLT2 inhibitors; Primary care</keywords><publishedDay>1</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-05-01</publishedDate><doi>10.1007/s13300-022-01242-y</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This work was supported by a grant from AstraZeneca in respect of medical writing and publication costs.</funders><projectreference/><lastEdited>2022-08-05T12:24:45.4909389</lastEdited><Created>2022-04-04T15:57:31.7237071</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Marc</firstname><surname>Evans</surname><order>1</order></author><author><firstname>Angharad R.</firstname><surname>Morgan</surname><order>2</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>3</order></author><author><firstname>Sarah</firstname><surname>Davies</surname><order>4</order></author><author><firstname>Umesh</firstname><surname>Dashora</surname><order>5</order></author><author><firstname>Smeeta</firstname><surname>Sinha</surname><order>6</order></author><author><firstname>Samuel</firstname><surname>Seidu</surname><order>7</order></author><author><firstname>Dipesh C.</firstname><surname>Patel</surname><order>8</order></author><author><firstname>Hannah</firstname><surname>Beba</surname><order>9</order></author><author><firstname>W. David</firstname><surname>Strain</surname><order>10</order></author></authors><documents><document><filename>59763__24064__376db24e641745b9b20c9724daa0f15e.pdf</filename><originalFilename>59763.pdf</originalFilename><uploaded>2022-05-13T13:42:02.9523402</uploaded><type>Output</type><contentLength>670193</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright: The Author(s) 2022. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-08-05T12:24:45.4909389 v2 59763 2022-04-04 Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2022-04-04 BMS Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the cardiovascular, renal and metabolic systems, through a continuous chain of events referred to as ‘the cardiorenal metabolic continuum’. Increasing evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes. Despite this robust evidence base, the complexity of label indications and misconceptions concerning potential side effects have resulted in a lack of clear understanding in primary care regarding the implementation of SGLT2is in clinical practice. With this in mind, we provide an overview of the clinical and economic benefits of SGLT2is across the cardiorenal metabolic continuum together with practical considerations in order to help address some of these concerns and clearly define the role of SGLT2is in primary care as a holistic outcomes-driven treatment with the potential to reduce disease burden across the cardiorenal metabolic spectrum. Journal Article Diabetes Therapy 13 5 889 911 Springer Science and Business Media LLC 1869-6953 1869-6961 Cardiorenal metabolic continuum; Chronic kidney disease; Diabetes; Heart failure; SGLT2 inhibitors; Primary care 1 5 2022 2022-05-01 10.1007/s13300-022-01242-y COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University This work was supported by a grant from AstraZeneca in respect of medical writing and publication costs. 2022-08-05T12:24:45.4909389 2022-04-04T15:57:31.7237071 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Marc Evans 1 Angharad R. Morgan 2 Steve Bain 0000-0001-8519-4964 3 Sarah Davies 4 Umesh Dashora 5 Smeeta Sinha 6 Samuel Seidu 7 Dipesh C. Patel 8 Hannah Beba 9 W. David Strain 10 59763__24064__376db24e641745b9b20c9724daa0f15e.pdf 59763.pdf 2022-05-13T13:42:02.9523402 Output 670193 application/pdf Version of Record true Copyright: The Author(s) 2022. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License true eng http://creativecommons.org/licenses/by-nc/4.0/
title Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
spellingShingle Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Steve Bain
title_short Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
title_full Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
title_fullStr Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
title_full_unstemmed Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
title_sort Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Marc Evans
Angharad R. Morgan
Steve Bain
Sarah Davies
Umesh Dashora
Smeeta Sinha
Samuel Seidu
Dipesh C. Patel
Hannah Beba
W. David Strain
format Journal article
container_title Diabetes Therapy
container_volume 13
container_issue 5
container_start_page 889
publishDate 2022
institution Swansea University
issn 1869-6953
1869-6961
doi_str_mv 10.1007/s13300-022-01242-y
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the cardiovascular, renal and metabolic systems, through a continuous chain of events referred to as ‘the cardiorenal metabolic continuum’. Increasing evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes. Despite this robust evidence base, the complexity of label indications and misconceptions concerning potential side effects have resulted in a lack of clear understanding in primary care regarding the implementation of SGLT2is in clinical practice. With this in mind, we provide an overview of the clinical and economic benefits of SGLT2is across the cardiorenal metabolic continuum together with practical considerations in order to help address some of these concerns and clearly define the role of SGLT2is in primary care as a holistic outcomes-driven treatment with the potential to reduce disease burden across the cardiorenal metabolic spectrum.
published_date 2022-05-01T04:17:19Z
_version_ 1763754156350242816
score 11.012813

Similar Items